James Galea - Concepedia

Author

James Galea

University of Manchester

Also Known As

J Galea, James Galea

Publications

962

Citations

H-Index

Concepts

All Affiliations

University of Manchester Salford Royal NHS Foundation Trust Manchester Academic Health Science Centre Ninewells Hospital

About

James Galea is an author at University of Manchester specializing in medicine, thrombosis, and stroke.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	237
2	Health Sciences	2	2	222
3	Neurology	2	2	222
4	Immunology	1	1	15
5	Neuroscience	1	1	112

James Galea

Publications

898

Citations

H-Index

Page 1

	Year	Citations
Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer’s disease in rodent models Michael J. Daniels, Jack Rivers‐Auty, Tom Schilling, Nature Communications	2016	429
The intrathecal CD163‐haptoglobin–hemoglobin scavenging system in subarachnoid hemorrhage James Galea, Garth Cruickshank, Jessica L. Teeling, Journal of Neurochemistry Delayed Cerebral IschemiaSignificant Intrathecal HemolysisIntrathecal Cd163‐haptoglobin–hemoglobinCerebral Vascular RegulationNeurovascular Disease	2012	112
Intravenous Anakinra can Achieve Experimentally Effective Concentrations in the Central Nervous System within a Therapeutic Time Window: Results of a Dose-Ranging Study James Galea, Kayode Ogungbenro, Sharon Hulme, Journal of Cerebral Blood Flow & Metabolism Cerebrovascular DiseasePharmacotherapyExperimental PharmacologyCerebral Vascular RegulationNeurovascular Disease	2010	110
[18F]DPA-714: Direct Comparison with [11C]PK11195 in a Model of Cerebral Ischemia in Rats Hervé Boutin, C. Prenant, Renaud Maroy, PLoS ONE	2013	87
Rapid brain penetration of interleukin‐1 receptor antagonist in rat cerebral ischaemia: pharmacokinetics, distribution, protection AD Greenhalgh, James Galea, Ádám Dénes, British Journal of Pharmacology	2010	72
Anakinra in COVID-19: important considerations for clinical trials Andrew T. King, Andy Vail, Claire O’Leary, The Lancet Rheumatology Covid-19 PandemicAntiviral TherapyClinical TrialsCovid-19 EpidemiologyCovid-19	2020	55
Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study Carlo Berzuini, Cathal John Hannan, Andrew T. King, BMJ Open	2020	18
Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist Kayode Ogungbenro, Sharon Hulme, Nancy J. Rothwell, Journal of Pharmacokinetics and Pharmacodynamics Study DesignMedicineInterleukin-1 Receptor AntagonistImmunologyPopulation Pharmacokinetic Analysis	2015	15

Page 1